Flexion Therapeutics Inc (OQ:FLXN)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 10 Mall Rd Ste 301
BURLINGTON MA 01803-4121
Tel: N/A
Website: flexiontherapeutics.com
IR: See website
<
Key People
Patrick J. Mahaffy
Independent Chairman of the Board
Michael D. Clayman
President, Chief Executive Officer, Director
David A. Arkowitz
Chief Financial Officer
Neil Bodick
Chief Scientific Officer
Mark Levine
General Counsel and Corporate Secretary
Scott D. Kelley
Chief Medical Officer
Kerry Wentworth
Chief Regulatory Officer
Christina Willwerth
Chief Strategy Officer
 
Business Overview
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Financial Overview
For the six months ended 30 June 2019, Flexion Therapeutics Inc revenues increased from $6M to $27.5M. Net loss decreased 9% to $78M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income increase from $219K to $535K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.27 to -$2.05.
Employees: 272 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $519.60M as of Jun 30, 2019
Annual revenue (TTM): $44.05M as of Jun 30, 2019
EBITDA (TTM): -$149.85M as of Jun 30, 2019
Net annual income (TTM): -$162.24M as of Jun 30, 2019
Free cash flow (TTM): -$158.12M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,106,641 as of Aug 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization